X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs CIPLA - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA CIPLA AUROBINDO PHARMA/
CIPLA
 
P/E (TTM) x 16.2 39.8 40.8% View Chart
P/BV x 4.1 3.7 111.5% View Chart
Dividend Yield % 0.4 0.5 82.5%  

Financials

 AUROBINDO PHARMA   CIPLA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
CIPLA
Mar-18
AUROBINDO PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs895663 135.0%   
Low Rs622479 129.9%   
Sales per share (Unadj.) Rs254.6189.0 134.7%  
Earnings per share (Unadj.) Rs39.317.6 223.2%  
Cash flow per share (Unadj.) Rs46.634.0 136.9%  
Dividends per share (Unadj.) Rs2.503.00 83.3%  
Dividend yield (eoy) %0.30.5 62.7%  
Book value per share (Unadj.) Rs160.0176.7 90.5%  
Shares outstanding (eoy) m585.88805.12 72.8%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x3.03.0 98.6%   
Avg P/E ratio x19.332.5 59.5%  
P/CF ratio (eoy) x16.316.8 97.0%  
Price / Book Value ratio x4.73.2 146.8%  
Dividend payout %6.417.1 37.3%   
Avg Mkt Cap Rs m444,390459,724 96.7%   
No. of employees `00014.023.6 59.2%   
Total wages/salary Rs m17,67826,901 65.7%   
Avg. sales/employee Rs Th10,667.86,446.1 165.5%   
Avg. wages/employee Rs Th1,264.31,139.4 111.0%   
Avg. net profit/employee Rs Th1,645.8600.0 274.3%   
INCOME DATA
Net Sales Rs m149,157152,193 98.0%  
Other income Rs m1,1593,577 32.4%   
Total revenues Rs m150,316155,769 96.5%   
Gross profit Rs m34,34328,264 121.5%  
Depreciation Rs m4,27613,228 32.3%   
Interest Rs m6671,142 58.4%   
Profit before tax Rs m30,55817,470 174.9%   
Minority Interest Rs m500-   
Prior Period Items Rs m0-28 0.0%   
Extraordinary Inc (Exp) Rs m0-775 0.0%   
Tax Rs m7,5972,501 303.7%   
Profit after tax Rs m23,01214,166 162.4%  
Gross profit margin %23.018.6 124.0%  
Effective tax rate %24.914.3 173.6%   
Net profit margin %15.49.3 165.8%  
BALANCE SHEET DATA
Current assets Rs m92,062108,141 85.1%   
Current liabilities Rs m66,22338,322 172.8%   
Net working cap to sales %17.345.9 37.8%  
Current ratio x1.42.8 49.3%  
Inventory Days Days10697 109.2%  
Debtors Days Days6874 90.9%  
Net fixed assets Rs m62,919109,411 57.5%   
Share capital Rs m5861,610 36.4%   
"Free" reserves Rs m93,133140,682 66.2%   
Net worth Rs m93,719142,292 65.9%   
Long term debt Rs m1,81436,621 5.0%   
Total assets Rs m162,494228,606 71.1%  
Interest coverage x46.816.3 287.2%   
Debt to equity ratio x00.3 7.5%  
Sales to assets ratio x0.90.7 137.9%   
Return on assets %14.66.7 217.6%  
Return on equity %24.610.0 246.6%  
Return on capital %32.710.0 328.9%  
Exports to sales %032.8 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA49,883 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m75,83851,691 146.7%   
Fx outflow Rs m30,22421,033 143.7%   
Net fx Rs m45,61330,658 148.8%   
CASH FLOW
From Operations Rs m32,78614,628 224.1%  
From Investments Rs m-17,870-8,540 209.3%  
From Financial Activity Rs m-19,153-3,855 496.9%  
Net Cashflow Rs m-4,2392,431 -174.4%  

Share Holding

Indian Promoters % 54.1 16.0 338.1%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 8.0 12.2 65.2%  
FIIs % 27.7 23.7 116.9%  
ADR/GDR % 0.0 1.1 -  
Free float % 10.2 26.2 38.9%  
Shareholders   69,601 161,166 43.2%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   STRIDES SHASUN LTD  AJANTA PHARMA  ALEMBIC LTD  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 12.0% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 12.0% YoY). Sales on the other hand came in at Rs 43 bn (up 15.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)

Aug 7, 2018

Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Aug 17, 2018 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - ALEMBIC PHARMA COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS